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Abstract
Background: Graft survival after kidney transplantation has significantly improved within the last decades but there
is a substantial number of patients with declining transplant function and graft loss. Over the past years several studies
have shown that metabolic acidosis plays an important role in the progression of Chronic Kidney Disease (CKD) and
that alkalinizing therapies significantly delayed progression of CKD. Importantly, metabolic acidosis is highly prevalent
in renal transplant patients and a recent retrospective study has shown that metabolic acidosis is associated
with increased risk of graft loss and patient death in kidney transplant recipients. However, no prospective
trial has been initiated yet to test the role of alkali treatment on renal allograft function.
Methods: The Preserve-Transplant Study is an investigator-initiated, prospective, patient-blinded, multi-center,
randomized, controlled phase-IV trial with two parallel-groups comparing sodium bicarbonate to placebo. The
primary objective is to test if alkali treatment will preserve kidney graft function and diminish the progression
of CKD in renal transplant patients by assesing the change in eGFR over 2 years from baseline. Additionally
we want to investigate the underlying pathomechanisms of nephrotoxicity of metabolic acidosis.
Discussion: This study has the potential to provide evidence that alkali treatment may slow or reduce the
progression towards graft failure and significantly decrease the rate of end stage renal disease (ESRD), thus
prolonging long-term graft survival. The implementation of alkali therapy into the drug regimen of kidney
transplant recipients would have a favorable risk-benefit ratio since alkali supplements are routinely used in
CKD patients and represent a well-tolerated, safe and cost-effective treatment.
Trial registration: ClinicalTrials.gov NCT03102996. Trial registration was completed on April 6, 2017.
Keywords: Metabolic acidosis, Sodium bicarbonate, eGFR, Graft outcome, Graft function
Background
The treatment of end-stage chronic kidney disease in-
cludes hemodialysis, peritoneal dialysis and kidney trans-
plantation (KTx), while today KTx is the treatment of
choice due to better survival, quality of life and cost ef-
fectiveness in comparison to maintenance dialysis [1, 2].
Short- and long-term graft survival after KTx have
significantly improved within the last decades but there
is still a substantial number of patients with declining
transplant function and graft loss in the long term. Cur-
rently, the mean 20-year graft survival is only 30–40%
[3]. Consequently, there is a clear need to develop and
test for new therapies that may help to preserve
long-term graft function. In addition, identification of re-
liable candidate biomarkers would allow predicting
long-term allograft function or select specific transplant
patients that may benefit from new strategies.
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Metabolic acidosis (MA) is a well-known complication
of CKD and associated with a variety of complications
such as uremic bone disease, protein-energy wasting,
chronic inflammation, insulin resistance, impairment of
myocardial function and disturbances in mineral
metabolism, growth hormone and thyroid gland function
[4–6]. In addition, observational studies have shown that
MA is associated with increased mortality in both, dialy-
sis patients and patients with non-dialysis dependent
CKD [7]. Importantly, MA is highly prevalent in renal
transplant patients with prevalences reported ranging
from 12 to 58% and seems to be consistently more fre-
quent and more severe when compared to
non-transplant CKD cohorts with similar degrees of
renal function [8–10]. In our clinic, a cross-sectional
analysis among 823 unselected kidney transplant pa-
tients revealed metabolic acidosis in 58.1% of the pa-
tients defined by a serum bicarbonate of < 24 mmol/l
indicating a high prevalence of MA in this patient co-
hort [8]. Notably, eGFR correlated best with serum bi-
carbonate levels at time of examination. These data
could be confirmed by other authors [9] and similar to
CKD patients creatinine clearance was markedly lower
in the group of transplant patients with MA compared
to the non-acidotic patients. Over the past few years sev-
eral studies have shown that MA plays an important role
in the progression of CKD and that low serum bicarbon-
ate levels are associated with a higher risk of progressing
to end-stage renal disease [5, 7, 11–15]. Amelioration of
MA in CKD patients with alkalinizing therapies delayed
progression of GFR loss [16–18]. Furthermore, a recent
study has shown for the first time that MA after KTx is
associated with increased risk of graft loss and patient
death as mentioned before for CKD patients. In this
multicenter retrospective cohort study of 2318 patients,
a low TCO2 level (< 22 mmol/L) 3 months after trans-
plantation was associated with increased risk of graft loss
and death-censored graft failure even after adjusting for
eGFR [19]. However, to the best of our knowledge, no
prospective trial has been initiated yet to test the role of
alkali treatment in the prevention of progressive loss of
renal allograft function.
Apart from the crucial question if alkali treatment may
have a beneficial effect on graft function there are at
least two other important aspects of metabolic acidosis
after kidney transplantation that are not fully understood
yet, namely first the underlying pathomechanisms why
MA occurs in KTx patients and second how metabolic
acidosis may promote disease progression. It has been
reported that MA is more common in patients who re-
ceived a cadaveric organ compared to a transplant from
a living donor [20] but as of today, the influence of
donor age, donor renal function and further
pre-transplant factors on the occurrence of MA after
KTx is still unclear [10]. Other factors such as the intake
of calcineurin inhibitors have been shown to be associ-
ated with the development of MA by specific changes in
tubular epithelial cells which play a role in acid-base
regulation [8, 20–24]. In CKD, Wesson et al. investigated
intensively the pathogenic effects of endothelin, aldoster-
one and angiotensin-II on the kidney and its impact on
GFR [13, 14, 17, 25–28]. Likewise, a role of the comple-
ment system and accumulation of interstitial ammonium
had been early proposed to contribute to progression of
CKD [29]. Thus, it is essential to investigate the role and
in particular the pathomechanisms of MA on graft func-
tion and outcome. These findings may help to develop
new potential therapeutic targets, such as alkali therapy,
that may help to preserve long-term graft survival in this
population.
To date, more than 3000 patients with a functioning
kidney transplant are living in Switzerland and over
200,000 in the United States [30]. Many of these patients
already suffer from decreased graft function which fa-
vours the development of MA. Given the expanding
pool of CKD patients - including former kidney trans-
plant recipients - an alkali treatment study in kidney
transplant patients is of prime importance and has the
potential to show that such a treatment may slow or re-
duce the progression towards graft failure and signifi-
cantly decrease the rate of end stage renal disease, and
therefore prolonging long-term graft survival in KTRs.
Methods
Trial design
The Preserve-Transplant Study (PTS) is an
investigator-initiated, prospective, patient-blinded,
multi-center, randomized, controlled phase-IV trial with
two parallel-groups comparing sodium bicarbonate to
placebo. The study encompasses 300 patients, ≥ 18 years
of age, at least 12 months after renal transplantation and
with a serum bicarbonate level ≤ 22 mmol/l. A placebo
was chosen as a comparator to the intervention because
no equivalent active comparator is existing to date that
would qualify as an appropriate comparator. Participants
will be randomly allocated to receive sodium bicarbonate
or placebo in a 1:1 distribution and will be followed up
for 2 years (see Fig. 1). The trial is performed at three
transplant centers in Switzerland, in Zurich, Berne and
Geneva.
Objectives and hypothesis
The primary objective of PTS is to test if alkali treat-
ment will preserve kidney graft function and diminish
the progression of chronic kidney disease in renal trans-
plant patients by assesing the change in eGFR over
2 years from baseline compared to placebo.
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Additionally we want to investigate underlying patho-
mechanisms of metabolic acidosis and how metabolic
acidosis may promote disease progression. A further ob-
jective is to identify reliable candidate biomarkers that
would allow selecting specific transplant patients that
may benefit from alkali therapy.
This study assesses long-term safety of the study drug
with a particular focus on new onset and worsening of
hypertension, volume overload, and gastrointestinal side
effects. Selected adverse events (AEs) and all serious ad-
verse events (SAEs) will be documented regularly and
compared between the treatment and placebo group.
Trial outcomes
The primary outcome of this study is the change in renal
function by assessing eGFR within 2 years. eGFR will be
determined based on the CKD-EPI creatinine equation.
By now, eGFR is the best parameter to assess kidney
function and to predict graft and patient survival in kid-
ney transplant recipients [1]. Recent recommendations
from the NKF-FDA Scientific Workshop and other pub-
lications show that eGFR decline over 2–3 years is an
acceptable endpoint for CKD progression trials and clin-
ical transplant research [1, 31–33]. Additionally, several
recent studies have used eGFR successfully to investigate
the effect of alkali treatment on progression of chronic
kidney disease [13, 14, 28]. Moreover, creatinine is a
well-established, standardized, and reliable parameter
ubiquitously measured in routine clinical practice and
compared to inulin or radiolabeled isotopes such as 125I
Iothalamate or 51Cr EDTA very cost-effective and easy
available.
Important secondary outcomes include changes in
serum bicarbonate levels, pH, sodium, potassium, and
proteinuria measured as protein/creatinine or albumin/
creatinine ratio in spot urine. As a safety outcome, 24-h
ambulatory blood pressure monitoring will be performed
at the beginning of the study and after 1 and 2 years to
evaluate the effect of sodium bicarbonate on blood pres-
sure. All outcomes of interest are shown in Table 1.
Study population
Kidney transplant patients will be recruited from all
study centers according to the inclusion and exclusion
criteria (Table 2).
Study enrolment, randomization and blinding
Potential candidates will be identified from the elec-
tronic hospital databases. After signature of the in-
formed consent and successful screening patients will be
randomized in a 1:1 ratio stratified by each study center
and gender using a permuted block design. The block
size will be concealed until the primary endpoint will be
analyzed. The randomization lists remain within the
electronic data management tool for the whole duration
of the study. Thus, randomization will be conducted
without any influence of the principal investigators or
other study personnel. The study is single-blind on the
patient side.
Biobank
Biobank samples are obtained at every study visit in all
study centers and stored at − 80 °C for 5 years after ter-
mination of the study according to Swiss legal require-
ments. All samples or genetic data will be stored and
used for future research purposes with the participant’s
consent.
Investigational medicinal product
Nephrotrans® (sodium hydrogen carbonate, ATC-Code:
A02AH) has been approved and used since 1986 for the
treatment of metabolic acidosis. Nephrotrans® is a safe,
well-tolerated drug with very few and well-studied side
effects. The study drug will be provided by SALMON
Pharma GmbH in its commercially available formula-
tion, used orally in this study and will be given at an ini-
tial dose of 500–1000 mg sodium hydrogen carbonate
Fig. 1 Study Flowchart of the Preserve-Transplant Study. Numbers in circles define each study visit. Study visits 2, 7, and 11 include in addition to
blood and spot urine tests 24 h-ambulatory blood pressure monitoring and 24 h urine collection
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thrice daily. The dosage is chosen according to the body
weight of the patient at baseline visit (< 70 kg or ≥
70 kg). If serum bicarbonate remains ≤22 mmol/l the
dosage of sodium hydrogen bicarbonate will be titrated
once to 1000–1500 mg thrice daily as for placebo too at
visit 3 after 2 weeks. All patients will be blinded to the
identity of the study drug. The study product will be ad-
ministered for a total of 2 years. The placebo is also pro-
vided by SALMON Pharma GmbH and used as a
comparator to the intervention in this study. All patients
will have the best standard care for kidney transplant
patients.
Informed consent
Written informed consent for participation will be ob-
tained from all participants before any study related ac-
tions are taken. Patients will be informed that
withdrawal from the study is possible at any time with-
out giving reasons.
Approvals
The study has been approved by the Cantonal Ethics
Committee of Zürich, Berne and Geneva and
Swissmedic as the competent authority. The study has
been registered on ClinicalTrials.gov (NCT03102996).
The project will be conducted in line with the Declar-
ation of Helsinki as well as all national legal and
regulatory requirements. In addition all researchers will
follow the GCP guidelines. All non-substantial and sub-
stantial amendments of the protocol will be reported to
the ethics committees and the competent authorities in
Switzerland.
Criteria for discontinuation
Patients will be withdrawn from participation in the
trial if they withdraw their consent or the investigator
or sponsor withdraws the patient because of malcom-
pliance with the study intervention. Additionally, if
serum bicarbonate exceeds 35 mmol/l or falls below
Table 1 Study Outcomes
Primary Outcome Change in renal function by assessing eGFR
(CKD-EPI) within 2 years
Important Secondary
Outcomes
Changes in serum bicarbonate levels, pH,
sodium, potassium, and proteinuria measured as
protein/creatinine or albumin/creatinine ratio in
spot urine
Safety Outcome Twenty-four-hour ambulatory blood pressure
monitoring will be performed at the beginning
of the study and after 1 and 2 years
Other Outcomes of
Interest
• Changes in measurement of specific acid base
transport proteins by urinary exosome
collection
• Changes in urinary ammonium excretion,
inflammatory markers such as complement
factors, and hormones involved in
tubulo-interstitial nephritis/fibrosis such as
endothelin and aldosterone
• Histopathological grade of tubulo-interstitial
fibrosis according to BANFF classification in
kidney biopsies (where available) will be
analyzed in both arms
• Systemic calcification propensity in blood will
be determined by the T50-Test (A test measuring
the transformation time (T50) of primary to
secondary calciprotein particles, where a long
delay of T50 indicates a high residual capacity of
the patients’ serum to prevent the formation of
secondary calciprotein particles and is therefore
a sign of an intact endogenous defense against
calcification) [34]
• Change of bone density and rejection rate
Table 2 Inclusion and Exclusion Criteria of the Preserve-
Transplant Study
Inclusion Criteria
• Informed consent as documented by signature
• Age≥ 18 years and able to give informed consent
• ≥ 12 months after renal transplantation
• Stable clinical condition
• Stable graft function over the last 6 months (creatinine
changes ±15%)
• eGFR between 15 and 89 ml/min/1.73 m2
• At least one serum bicarbonate measured ≤22 mmol/l within
the last 6 months
Exclusion Criteria
• Uncontrolled hypertension or use of > 4 antihypertensive agents
• Uncontrolled heart failure
• Serum potassium < 3.0 mmol/l
• Serum sodium > 150 mmol/l
• Use of alkali in the preceding 4 weeks
• Use of mineralocorticoid antagonists, topiramate, carbo anhydrase
inhibitors or any drugs with similar effects
• History of noncompliance with clinic visits
• Hereditary fructose intolerance
• Known hypersensitivity or allergy to the drug used in this study
or to peanut, sorbitol, and soy
• Pregnancy or breastfeeding
• Intention to become pregnant during the course of the study
• Lack of safe contraception, defined as: Female participants of
childbearing potential, not using and not willing to continue using a
medically reliable method of contraception for the entire study
duration, such as oral, injectable, or implantable contraceptives, or
intrauterine contraceptive devices, or who are not using any other
method considered sufficiently reliable by the investigator in
individual cases. Please note that female participants who are
surgically sterilised / hysterectomised or post-menopausal for longer
than 2 years are not considered as being of child bearing potential.
• Suspected drug or alcohol abuse
• Inability to follow the procedures of the study, e.g. due to language
problems, psychological disorders, dementia, etc. of the participant
• Enrolment of the investigator, his/her family members, employees
and other dependent persons
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16 mmol/l the patient will have to be excluded from
the study for safety reasons. Pregnancy in women or
a significant violation of the protocol as judged by
the coordinating investigator also will lead to with-
drawal of the participant. Patients will be withdrawn
from study treatment permanently if a severe allergic
or hypersensitivity reaction to the drug occurs or if
the investigator feels that the treatment is harmful to
the subject. In case of a treatment-related SAE the
study drug will also be withdrawn from the patient. A
study patient who discontinues study participation
prematurely for any reason is defined as dropout if
the subject has already been randomized. A study pa-
tient who terminates the study before randomization
is regarded as a screening failure.
Monitoring
Quality assurance will be based on a central and on-site
monitoring. The central monitoring encompasses moni-
toring of data entry progress. Trial sites will also be
regularly visited by independent monitors. Visits will
focus on controlling regulatory compliance, monitoring
of processes, and verification of data that cannot be
monitored centrally.
Data management
In the Preserve-Transplant study, all data will be en-
tered electronically using an internet-based secure
data base (secuTrial®) developed in agreement with
the Good Clinical Practice (GCP) guidelines. Data
integrity is enforced through a variety of mecha-
nisms. Regular backup of the data is assured.
Statistical analysis
The analysis population consists of all patients who
were randomized and have valid data for baseline
and at least one follow-up. The primary and
secondary endpoints will be analyzed with linear
mixed models. Moreover, exploratory subgroup ana-
lyses are planned with respect to baseline eGFR to
evaluate whether subgroups with lower baseline
eGFR will show a better response to alkali treatment
compared to subgroups with higher baseline eGFR.
Any further details will be specified in the statistical
analysis plan.
Sample size
Based on a retrospective analysis of our own cohort,
it was assumed that the mean annual eGFR decline in
the placebo group will be 1.5 ml/min/1.73 m2 and
that this decline can be reduced to 0 ml/min/1.73 m2
in the treatment group as a result of alkali therapy
based on previously published data for CKD patients
with metabolic acidosis. Power was determined on
the basis of a two-sided, two-sample t-test of the
slopes over 2 years. Group sizes of 150 will achieve
82% power to find a minimum detectable difference
in the mean slope over 2 years of − 3.0 with esti-
mated group standard deviations of 9.0 and with a
significance level of 0.05 using a two-sided
two-sample t-test. Therefore, a total number of 300
patients for the entire study is planned.
Discussion
Metabolic acidosis is a serious complication in patients
with CKD with deleterious effects on kidney function
and patient survival. A recent retrospective study has ev-
idenced that MA is also associated with increased risk of
graft loss and patient mortality in kidney transplant re-
cipients [19]. Although several studies have demon-
strated a beneficial role for alkali therapy on the
progression of CKD [5, 7, 11–15], no data is available if
alkali treatment may also allow to better preserve renal
allograft function in kidney transplant recipients with
metabolic acidosis.
The Preserve-Transplant Study is the first
investigator-initiated prospective clinical trial that
aims to test whether alkali treatment will help pre-
serving kidney graft function and diminish the pro-
gression of chronic kidney disease in renal transplant
patients. Thereby, alkali therapy may have the poten-
tial to become the first evidence-based adjuvant ther-
apy for the preservation of graft function in kidney
transplant patients.
Consequently, the results of the PTS may provide
evidence to adapt current recommendations and
guidelines for the routine treatment of KTRs suffering
from metabolic acidosis. The increasing demand for
donor organs worldwide calls for solutions to help to
prolong graft survival. The implementation of alkali
therapy into the drug regimen of kidney transplant
recipients would have a favorable risk-benefit ratio
since alkali supplements are routinely used in CKD
patients and represent a well-tolerated, safe and
cost-effective treatment.
Trial status and dissemination
The Preserve-Transplant randomized controlled clin-
ical study has received governance approval and is
registered at ClinicalTrials.gov (NCT03102996). The
trial started recruitment in June, 2017. The study will
end in June 2021. First results from this trial are ex-
pected in the first quarter of 2022. Publications will
be submitted to peer-reviewed journals and the re-
sults will be presented at national and international
scientific conferences.
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